Paracelsus Course Objectives: Toxicology for the Laboratory Animal Scientist. General Toxicology Investigations. Reproductive Toxicology

Similar documents
Preclinical studies needed in the development of human pharmaceutical drugs role of toxicology and risk assessment

Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations Guidance for Industry

Regulatory compliance in Non-Clinical development

Basic principles of the safety assessment of drugs

MAINTENANCE OF THE ICH GUIDELINE ON NON-CLINICAL SAFETY STUDIES FOR THE CONDUCT OF HUMAN CLINICAL TRIALS FOR PHARMACEUTICALS M3(R1)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE

Structure and content of an IMPD. What is required for first into man trial?

Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective

Detection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members

S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

Guidelines and criteria for seeking approval to conduct clinical trials in Ayurveda, Siddha and Unani system.

06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND

PRECLINICAL DRUG DISCOVERY AND DEVELOPMENT BIOBOOT CAMP 2016

Biological evaluation of medical devices. Part 11: Tests for systemic toxicity

Optimisation de votre programme de développement

Comments and suggestions from reviewer

Medical Device Testing. Andrew Makin, MSc, ERT, MRSB Scientific Director CiToxLAB Scantox, Denmark

Writing an IACUC Protocol

From Drug Discovery to IND Saving Time and Money Through Smart Study Design

ICH Topic M 3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals.

ILSI AGRICULTURAL CHEMICAL SAFETY ASSESSMENT (ACSA) PROJECT: A TIERED TESTING APPROACH. November 18, 2005

International Council for Harmonisation (ICH) Safety Guideline Updates

Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität

Bioanalytical Support to In Vitro Studies

EVALUATION OF THE SAFETY OF VETERINARY MEDICINAL PRODUCTS FOR THE TARGET ANIMALS

Transmission to CHMP July Adoption by CHMP for release for consultation 20 July Start of consultation 31 August 2017

ICH CONSIDERATIONS Oncolytic Viruses

Exploratory clinical trials workshop

OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -

This training module covers the following animals housed in vivaria: rodents rabbits birds amphibians reptiles non-human primates other mammals

NON-CLINICAL LOCAL TOLERANCE TESTING OF MEDICINAL PRODUCTS

Dermal Studies at CBI

STUDIES TO EVALUATE THE SAFETY OF RESIDUES OF VETERINARY DRUGS IN HUMAN FOOD: GENERAL APPROACH TO TESTING

THE ANSWERS YOU NEED ARE ALL RIGHT HERE

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers

REQUEST FORM FOR RESEARCH PROTOCOL APPROVAL. For IACUC Use Only: Major Survival Surgery Pain Category E studies Hazardous Agents

Guidance for Industry

QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING

First-in-human clinical trials Behind the scenes

Global Development Challenges: Classical and Advanced Therapy Medicinal products

ICH Considerations. Oncolytic Viruses September 17, 2009

Guideline on repeated dose toxicity

Juvenile toxicity studies with biopharmaceuticals : considerations and current practices

The TetraQ Difference. Quality Preclinical Drug Development Solutions. Provide advice and tailored solutions, not just a menu of choices

! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General

Guideline on the non-clinical requirements for radiopharmaceuticals

S3A:Note for guidance on toxicokinetics: The assessment of systemic exposure in toxicity studies. Q&A: FOCUS ON MICROSAMPLING

FDA Perspective on the Preclinical Evaluation of Biological Therapies for Cancer

Natural Products and Drug Discovery

Exploratory IND: a study proposal from Novartis

Investigational New Drug Application

Re: Docket No. FDA-2015-D-1246: Draft Guidance on Investigational Enzyme Replacement Therapy Products: Nonclinical Assessment

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers

Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.

Impurities in Drugs: Monitoring, Safety and Regulation The Israel Chapter of PDA

ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008

Oncology Biopharmaceuticals and Preclinical Development: Evolving Regulatory Challenges

Chapter 21. Toxicity Testing

PIP s Pup s and Problems

Ames Data Submissions and Other Qualification Data for Impurities in Drug Substances

TOXICOLOGY AND PHARMACOLOGY IN LABORATORY ANIMAL PATHOLOGY AND MEDICINE

Preclinical safety testing of diagnostic and therapeutic radiopharmaceuticals - regulatory requirements

From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager

Drug Development / Testing

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS

Dr. D. S. Rathore Rajasthan Pharmacy College

Vertebrate Animal Use Protocol for Research or Testing

ICH S9 guideline on nonclinical evaluation for anticancer pharmaceuticals - questions and answers

An Introduction to Clinical Research and Development

Preclinical study. Assist.Prof. Witthawat Wiriyarat Faculty of Veterinary Science, Mahidol University

Re: Docket No. FDA-2009-D-0006 S9 Nonclinical Evaluation for Anticancer Pharmaceuticals

CITI Certificates

WICHITA STATE UNIVERSITY INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) ANIMAL PROTOCOL FORM

Envigo Corporate & Industry Overview. Rutgers University

Development of a new medicinal product. as. MUDr. Martin Votava, PhD.

Supplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester

Introduction to Toxicologic Clinical Pathology

Harlan Laboratories. Contract Research Services

Institute of Pharmaceutical Technology and Biopharmacy University of Pécs szeptember 22. 1

Public Interest Incorporated Foundation BioSafety Research Center

Agreed with W. Cornell Graduate Program and Tri-I

S9 Implementation Working Group ICH S9 Guideline: Nonclinical Evaluation for Anticancer Pharmaceuticals Questions and Answers

Test compound and controls 1. The test compound or mixture was unlikely to contain any impurities that may significantly have affected its toxicity.

Registration of Proprietary Chinese Medicine!

Phase 1 Clinical Studies First-In-Human (FIH) <Chapter 31> Pharmacologically-Guided Dose Escalation

International Consortium For Innovation & Quality in Pharmaceutical Development

SEND Introduction CDISC User Group Meeting. Gitte Frausing. Principal Consultant Data Standards Decisions. Insight Interpretation Implementation

SAFETY RESEARCH INSTITUTE FOR CHEMICAL COMPOUNDS CO., LTD.

Our Business. in vitro / in vivo. in vitro / in vivo ADME. in vitro / in vivo. Toxicology. Cell Battery V79. Analytical Services. Service.

VICH Topic GL44. at Step 4 GUIDELINE ON TARGET ANIMAL SAFETY FOR VETERINARY LIVE AND INACTIVATED VACCINES

What can be done from regulatory side?

ICH Topic S 6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. Step 5

Supplementary exam work (Number, form, scope) Courses (type of teaching) Contact time. Winter semester

Combination Drug Applications: Nonclinical Reviewer Perspectives. Jessica J. Hawes, Ph.D.

Non-clinical documentation Overview of Requirements

Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety

Guide to Services Our service map.

ADVANCES IN PHARMACEUTICAL INDUSTRY FOR WELLNESS AND SUSTAINABLE HEALTH

Transcription:

Toxicology for the Laboratory Animal Scientist CL Davis Foundation Topics in Laboratory Animal Medicine May 7, 2009 Angela King-Herbert, DVM, DACLAM NTP/NIEHS RTP NC Course Objectives: Define terms used in the toxicology environment Discuss different types of toxicology studies Discuss the governing regulations in the toxicology environment Review the importance of laboratory animal science issues on toxicology data collection Paracelsus 1493-1541 1541 Many Types of Toxicology Studies!! What is not a Poison? General toxicology Ecotoxicology All things are poisons and nothing is without toxicity. Genetic toxicology Metabolism The right dose differentiates a poison from a remedy. Reproductive Safety pharmacology General Toxicology Investigations Homogeneity and stability Clinical observations Body weights, food/water consumption Ophthalmoscopic examinations Electrocardiogram Hematology, clinical chemistry, urinalysis, biomarkers Necropsy, lesions, organ weights Histopathology Reproductive Toxicology Fertility Organogenesis Fetal development Investigations - embryo count - fetal morphology - pup development - reproductive performance

Genetic Toxicology Prediction of genetic damage to humans by: in vitro gene mutation studies (bacteria, mammalian cells) chromosome damage (in vitro and in vivo) Ames test, mouse lymphoma assay, SHE assay etc. Safety Pharmacology Safety studies Acute effects Conscious and anaesthetized preparations Major functions, especially CNS and CV In vitro studies Pharmacokinetics Dedicated to the determination of the fate of substances administered to a living organism. Pharmacokinetics is often divided into several areas including, but not limited to, the extent and rate of Absorption, Distribution, Metabolism and Excretion. This sometimes is referred to as the ADME scheme. Drug Metabolism Absorption - how much drug gets into the body Distribution - where does the drug go in the body Metabolism - is the drug changed in the body Excretion - how does the drug (or metabolites) leave the body Selection of Species Toxicokinetics is the application of pharmacokinetics to determine the relationship between the systemic exposure of a compound in experimental animals and its toxicity. It is used primarily for establishing relationships between exposures in toxicology experiments in animals and the corresponding exposures in humans. Toxicokinetics measure exposure to drug (or metabolites)

Designing Studies Which Route? Designing Studies What Dose? Same as human Main routes - Oral, Intravenous Other routes - Inhalation, Ocular, Dermal, Intrathecal, Diet No dose - controls necessary Low dose - no toxic effect Mid dose - show some toxicity High dose - limited by toxicity or exposure Designing Studies - For how long? Depends upon clinical plan 1 day in humans 14 days study 7-14 days 14-28 days 1 month 1-6 months 1 year 6-12 months plus carcinogenicity studies Toxicity Testing Generally conducted in healthly, experimental animals (not in animal disease models). Some in vitro tests. Required by law for international regulatory agencies. Highly regulated area (GLPs). Study Design Study design is flexible and is based on regulatory agency recommendations and the International Conference on Harmonization (ICH) Guidelines. Good Laboratory Practice Regulations (GLPs) Promulgated into law by FDA in 1978 due to documentation problems in a contract toxicology laboratory. Terms - Sponsor is the commercial company that conducts the preclinical toxicity study in-house or at contract. FDA does not conduct the study. Scope - support for marketing applications to the FDA for food and color additives, animal food additives, human and animal drugs, medical devices, and biological and electronic products.

Good Laboratory Practice Regulations (GLPs) Study Director (Sponsor) (21 CFR 58.33) - overall responsibility for the technical conduct of the study as well as for the interpretation, documentation and reporting of results and represents the single point of study control. Quality Assurance Unit (Sponsor) (21 CFR 58.35) - to assure that facilities, equipment, personnel, methods, practices, records and controls are in conformance. Good Laboratory Practice Regulations (GLPs) Standard Operating Procedures (Sponsor) (21 CFR 58.81) - must have laboratory study methods in writing. Deviations authorized by Study Director. Protocol (Sponsor) (21 CFR 58.120) - each study shall have an approved written protocol. Requires dated signature of the Study Director. Revisions signed by Study Director and maintained with protocol. It s s critical to understand what the GLP s s are and how they came about. A process for study conduct and documentation that leads to reconstructability One can conduct a poorly designed study with full GLP compliance and likewise some of the best studies in science would never be amenable to compliance. There are numerous inherent conflicts in the conduct of toxicology studies that require the application of compromise and balance What is best for the animal may not be best for the study Each member of the study team has a differing role and responsibility Study design is often a series of compromises between animal welfare, personal safety, and scientific concerns The Partnership Veterinarians need to understand why the study is being conducted and the desired toxic endpoint This is best accomplished when the veterinary and toxicology staff communicate about the project ahead of time. ICH Guidance Documents Regulatory Web Sites for ICH Guidance: US Food and Drug Administration http://www.fda.gov/cder/guidance/index.htm European Agency for the Evaluation of Medicinal Products http://www.eudra.org/humandocs/humans/ich.htm

Numerous Animal Care and Use Issues in Developing Safety Protocols Species and Strains Use of transgenic animals Age Method of release of Source of animals for in- animals for use in studies house studies and contract Maximum dose volumes studies Maximum blood sample Group vs single housing of volumes rodents Maximum intravenous Duration of carcinogenicity injection rates studies Subcutaneous injection Selection of nonrodent limits species Diets Use of non-standard Bedding species, e.g., minipigs, ferrets Drinking water Environmental conditions (T/UR, lighting, caging, etc.) What influences data? Microbial status Diseases and lesions Genetics Environment Toxicology study methods Animal care and use program Safety study challenges Regulatory requirements lead to template studies in protocol development Difficulty of putting professional judgement into the framework of working in an SOP format Working in the world of CRO s Tendency to look at the record (data) versus the animal and the environment The Historical Toxicology Database Databases are living documents and change all the time Not a reason to abandon professional judgement Has held back advancements in animal care and use on safety studies Toxicologist vs Rodent Enrichment Turner et al., JAALAS, 42 (6), p 10

Stress Noise (Turner, 2005): maintenance, technical devices, animals Non-auditory effects of sound in laboratory animals: Cardiovascular: increased vasoconstriction and respiration in the rat Hormonal: increased norepinephrine, cortisol, cholesterol and plasma corticosterone in rat Other: increased microvascular permeability and disruption of the intestinal lining, decreased body weight Cage environment: Cage change: (Sharp, 2003) Witnessing a routine cage change induced significant increases in HR in rates. Witnessing restraint and SQ or tail-vein injections of other rats. Social: mixed information Stress Procedures: Stress (as measured by blood glucose and corticosterone) was significantly less in animals cannulated vs. animals that were repeatedly anesthetized for blood collection (Vachon, 2001). Long term activation of the HPA axis has been linked to immunosuppression, insulin resistance, hypertension and arteriosclerosis, catabolism, and GI problems Stress Facility/quarantine Staff Pre-study assessments Equipment Study procedures Acclimation Important to evaluate animals and not data alone: There is no substitution for looking at the animal in it s s environment Sentinel surveillance Design programs around the species, origin and duration of animal stay Rodent sentinel programs: Will animals stay long enough to warrant serologic evaluation? Do you have a sense of comfort about the disease status of the animals?

What constitutes normal? Having a control may not suffice Toxicologists place too much emphasis on comparing treated with control without considering what is normal Neurologic examinations in laboratory beagles Health Surveillance Dogs: Vendor? Quarantine period? Stock animal management? Dose Administration Dosing Issues Avoid excessive dose Information search Pilot studies Modeling Tiered approach Avoid unnecessary severity Limit use of positive control groups Aggressive moribund sacrifice Database search and information background Vehicle and formulation considerations Post-procedural observations and care Experimental manipulations Define in writing lines of consult and what is to be done Establish Procedures for Post-dosing Observations Train personnel in species specific behaviors Observe immediately post-dosing and a short time interval later (30-60 minutes) Observe animals next morning with clinical assessment Schedule assessments based on toxicant, target organ of toxicity and experience Automated Data Collection Systems Rapidly assess groups Handle large numbers of animals body weights, food and water consumption, clinical signs, mass tracking Forces standardization Training tool with prompts

Body Weight Determinations Tracking of groups Inherent limitations Trends more important than absolute Need to compare groups Clinical Assessment Usually the cases are noted on scheduled animal observations. To be considered: What is the category of toxicant? When was the study started? When does it end? How many are affected? What treatment group do they represent? Useful tools Trends in body weights Food consumption information-general Previous data from mechanistic studies Previous information from DRF or MTD studies Data from same class of drug Clinical data pk data Treatment modalities Canned or soft food Nutritional supplements Soft bedding Water bowls Subcutaneous fluid therapy Others? Humane Endpoints Unresponsiveness or coolness to the touch Progressive weight loss (Ullman-Cullere Cullere and Foltz, 1999) Prolonged recumbancy Seizures, respiratory distress Chronic diarrhea.. Decision Making Work with the SD Decide if the data that is sought has been obtained. Consider what is lost from the study if euthanasia occurs What is the justification for pain/distress?

Acknowledgements Many thanks to Dr. Mary Ann Vasbinder for the use of these slides and assistance with this presentation. References: Hutchinson, Avery and VandeWoude. 2005. Environmental enrichment t for laboratory rodents, ILAR 46, 2 pp. 148-161. 161. Turner PV, et. al. 2003 Refinements in the care and use of animals in toxicology studies-regulation, validation and progress. JAALAS. 42,6 pp 8-8 15. Sauer, MB et. al. 2006. Clinical pathology laboratory values of rats housed in wire-bottom cages compared with those of rats housed in solid-bottom cages. JAALAS 45,1 pp. 30-35. 35. Dean, SW. 1999. Environmental enrichment of laboratory animals used in regulatory toxicology studies. LA 33, 309-327. 327. Olson, H. et. al. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Reg. Tox. And Pharm. 32 56-67. 67.